Ozempic and Semaglutide Tablets: Licences, Names and What's Actually Available

Step 1: Understand that 'semaglutide tablets' and Ozempic are not the same product

A great deal of confusion online stems from the fact that semaglutide appears under several brand names, in different forms, for different conditions. Ozempic is an injectable semaglutide pen made by Novo Nordisk and has held a UK licence for type 2 diabetes management since 2019. It was never licensed for weight loss in the UK, and there is no Ozempic tablet. When people search for semaglutide tablets alongside the Ozempic name, they are usually looking for an oral version of the same drug, something that, for weight management, now exists but goes by a different brand name entirely.

The relevant oral product is Wegovy tablets, approved by the MHRA on 11 June 2026, making the UK the first country in Europe to grant the licence. It is taken once daily, starting at 1.5 mg and escalating through 4 mg and 9 mg to a 25 mg maintenance dose, a schedule set by the prescriber and described fully in the Wegovy tablet SmPC on the eMC. None of those dose steps overlap with the Rybelsus diabetes tablet strengths, so the two products should never be conflated. The question of whether semaglutide tablets are the same as Ozempic has a clear answer: same active molecule, different form, different licence, different clinical purpose.

Understanding the distinction is not a technicality, it directly affects what a prescriber can legally issue and why.

Step 2: Know what the oral semaglutide tablet is actually licensed to do

Wegovy tablets are licensed for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. They are taken first thing in the morning on an empty stomach with a small amount of plain water (roughly 120 ml) and the NHS advises waiting at least 30 minutes before eating, drinking anything else (including coffee) or taking other oral medicines. The tablet should be swallowed whole. Unlike Wegovy injections, no refrigeration is required, which makes day-to-day life considerably simpler for many people, travelling with a tablet in a washbag is straightforward in a way that a temperature-sensitive injectable is not.

In the OASIS 4 phase-3 trial, participants taking oral semaglutide lost an average of around 13.6% of body weight compared with roughly 2.4% in the placebo group over 64 weeks, alongside lifestyle changes. Among those who adhered fully to treatment, average loss reached approximately 16.6%. The NHS semaglutide medicines page is the clearest UK patient-level resource for further detail on how semaglutide works and what to expect. For anyone curious about the biological mechanism, our page on how oral semaglutide works covers the GLP-1 receptor pathway in plain language.

Oral semaglutide is not currently available through the NHS for weight management, a NICE appraisal process would need to take place first. Private prescription is the current route.

Step 3: Separate Ozempic, Rybelsus and Wegovy tablets clearly

Three semaglutide products are on the UK market. Ozempic (injectable, weekly, diabetes licence) and Rybelsus (oral, daily, diabetes licence, at 3 mg, 7 mg and 14 mg strengths) are both prescribed by GPs managing type 2 diabetes. Wegovy injections have held a UK weight-management licence since 2023 under NICE appraisal TA875, and the newer Wegovy tablet joined them in June 2026. For the relationship between Rybelsus and Ozempic, the shared active ingredient masks very different clinical contexts.

Prescribing Rybelsus or Ozempic for weight loss would be outside their UK licences, an off-label use that requires specific justification. A prescriber assessing someone for weight management would be working within the Wegovy injection or Wegovy tablet licence, not Ozempic's. The price context differs too: for a full picture of what oral semaglutide treatment typically costs privately, our cost guide covers what to look for and what legitimate pricing includes.

None of this means Ozempic is ineffective or inferior, it simply means it exists for a different clinical purpose. Reaching for it as a weight-loss medicine, particularly from unverified online sources, involves real risk: the MHRA has warned repeatedly about counterfeit semaglutide pens circulating without a prescription, and enforcement in 2025 led to the seizure of approximately 20 million doses of illegally traded weight-loss medicines worth around £45 million. A genuine semaglutide product for weight loss, prescribed through a GPhC-registered pharmacy, is the only safe route.

What IS licensed for weight loss, and how a clinical assessment works

If you are looking for weight-management treatment involving semaglutide, the licensed UK options are the Wegovy weekly injection and, since June 2026, the Wegovy daily tablet. Tirzepatide (Mounjaro) is the other licensed option, a dual GIP and GLP-1 receptor agonist with a different mechanism and a separate evidence base. An overview of weight-loss treatments available in the UK sets out the options side by side.

At nume, a GPhC-registered Independent Prescriber (a named clinician, not automated software) reviews every consultation personally, typically the same day it is submitted. They assess your medical history, current medicines, BMI and weight-related conditions before any prescription is issued. Our prescribers are listed on the clinical team page. The consultation itself is free, and if treatment is approved and ordered before midday on a working day, it is dispatched the same day and delivered free the next working day by DPD in plain packaging. Eligibility for the Wegovy tablet or injection, or for Mounjaro, is something our team can walk you through properly. If you have questions before starting, the FAQs page covers the most common ones. When you are ready to check whether you qualify, you can check your eligibility with a free consultation.